Spots Global Cancer Trial Database for bevacizumab
Every month we try and update this database with for bevacizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | NCT00473590 | Multiple Myelom... | Bevacizumab Bortezomib placebo | 18 Years - | Genentech, Inc. | |
| A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | NCT00993044 | Refractory Soli... | Irinotecan Vincristine Temozolomide Bevacizumab | 12 Months - 20 Years | Children's Hospital Los Angeles | |
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00409565 | Head and Neck C... Squamous Cell C... | Cetuximab Bevacizumab | 18 Years - 98 Years | National Cancer Institute (NCI) | |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 | Melanoma | bevacizumab carboplatin paclitaxel placebo | 18 Years - | Genentech, Inc. | |
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | NCT06139211 | Advanced Solid ... | JS015 Toripalimab Paclitaxel Irinotecan Capecitabine Oxaliplatin Bevacizumab Fluorouracil Leucovorin Gemcitabine Albumin-Bound P... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | NCT02563002 | Colorectal Carc... | mFOLFOX6 FOLFIRI pembrolizumab bevacizumab cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated | NCT00025337 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | bevacizumab oxaliplatin leucovorin calc... fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | NCT01229943 | Advanced Pancre... Locally Advance... Pancreatic Gast... Pancreatic Neur... Pancreatic Neur... Pancreatic Vipo... | Bevacizumab Everolimus Octreotide Acet... | 18 Years - | National Cancer Institute (NCI) | |
| A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel | NCT01722968 | Breast Cancer | Bevacizumab Paclitaxel | 18 Years - 70 Years | Karolinska University Hospital | |
| Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | NCT00321646 | Prostate Cancer Adenocarcinoma ... | Bevacizumab Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | NCT02810457 | Carcinoma, Non-... | FKB238 (bevaciz... Avastin (bevaci... Paclitaxel Carboplatin | 18 Years - | Centus Biotherapeutics Limited | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | NCT04627363 | Hepatocellular ... Bevacizumab Liver Neoplasms Toripalimab Oxaliplatin | Hepatic arteria... Bevacizumab Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00482495 | Multiple Myelom... | bevacizumab gene expression... protein express... laboratory biom... | 18 Years - | Mayo Clinic | |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis | NCT01332929 | Metastatic Mali... | Bevacizumab | 18 Years - 70 Years | Centre Francois Baclesse | |
| Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | NCT00280007 | Hepatocellular ... | bevacizumab | 18 Years - 85 Years | Medical University of Vienna | |
| A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | NCT00957125 | Breast Cancer | Epirubicin Docetaxel Bevacizumab | 18 Years - | Karolinska University Hospital | |
| A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | NCT04677504 | Biliary Tract C... | Atezolizumab Bevacizumab Placebo Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | NCT00137774 | Neuroendocrine ... | Bevacizumab Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00081861 | Lymphoma | Avastin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | NCT04721132 | Resectable Hepa... Stage I Hepatoc... Stage IA Hepato... Stage IB Hepato... Stage II Hepato... | Atezolizumab Bevacizumab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | NCT01069328 | Carcinoma, Non-... Lung Cancer | Nexavar (Sorafe... Nexavar (Sorafe... Bevacizumab Bevacizumab Bevacizumab Bevacizumab Paclitaxel Carboplatin | 18 Years - | Bayer | |
| Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | NCT02330783 | Metastatic Rena... | Bevacizumab Sorafenib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer | NCT01661790 | Malignant Pleur... | Bevacizumab Cisplatin | 18 Years - 85 Years | Chinese PLA General Hospital | |
| Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | NCT01182350 | Diffuse Intrins... | Bevacizumab Erlotinib Temozolomide Radiation | 3 Years - 18 Years | Dana-Farber Cancer Institute | |
| BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | NCT01562028 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | NCT03367871 | Cervical Cancer | Pembrolizumab Paclitaxel Cisplatin Carboplatin Bevacizumab | 18 Years - | University of Miami | |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | NCT01269853 | Glioblastoma Mu... Anaplastic Astr... | Bevacizumab Bevacizumab | 18 Years - | Northwell Health | |
| Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | NCT00537823 | Colorectal Canc... Metastases | Cetuximab Bevacizumab Leucovorin Oxaliplatin Fluorouracil | 18 Years - | Washington University School of Medicine | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy | NCT04812002 | Gestational Tro... | PD-1 inhibitor，... | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | NCT03462212 | Advanced (Stage... | Carboplatin Paclitaxel Bevacizumab Rucaparib | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer | NCT00062426 | Colorectal Canc... | bevacizumab capecitabine fluorouracil leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | NCT02497157 | Metastatic Colo... | Oxaliplatin (L-... Irinotecan hydr... Continuous intr... Levofolinate ca... Bevacizumab (Bm... | 20 Years - 70 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | NCT06225622 | Metastatic Colo... | Irinotecan Lipo... Oxaliplatin 5-FU LV Bevacizumab Cetuximab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Evaluation of Protein in the Urine in Patients Receiving Bevacizumab | NCT00849394 | Colon Cancer Rectal Cancer | 18 Years - | North Texas Veterans Healthcare System | ||
| A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | NCT00130728 | Non-Small Cell ... | bevacizumab erlotinib HCl placebo | 18 Years - | Genentech, Inc. | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | NCT03272217 | Urothelial Carc... | Atezolizumab Bevacizumab | 18 Years - | Hoosier Cancer Research Network | |
| Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery | NCT00305825 | Breast Cancer | bevacizumab letrozole | 18 Years - 120 Years | University of California, San Francisco | |
| Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | NCT00096278 | Colon Adenocarc... Stage IIA Colon... Stage IIB Colon... Stage IIC Colon... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... | Bevacizumab Fluorouracil Leucovorin Calc... Oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | NCT01632228 | Glioblastoma | Bevacizumab Onartuzumab Placebo | 18 Years - | Hoffmann-La Roche | |
| FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | NCT01133990 | Colorectal Canc... | FOLFIRI E7820 Bevacizumab | 18 Years - | Eisai Inc. | |
| Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | NCT00450827 | Neuroblastoma | bevacizumab filgrastim autologous hema... iodine I 131 mo... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | NCT00571740 | Colorectal Canc... | bevacizumab cetuximab fluorouracil leucovorin calc... oxaliplatin | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | NCT03063762 | Renal Cell Carc... | Atezolizumab Bevacizumab RO6874281 | 18 Years - | Hoffmann-La Roche | |
| De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | NCT02842580 | Colorectal Neop... | 5 FLUOROURACYL acide folinique irinotecan Oxaliplatin capécitabine bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | NCT04487067 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer | NCT00846027 | Breast Cancer | Bevacizumab Paclitaxel Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer | NCT00440973 | Carcinoma, Rena... | Bevacizumab Interleukin-2 | 18 Years - | The Methodist Hospital Research Institute | |
| Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | NCT00753909 | Non Small Cell ... | Carboplatin Bevacizumab Paclitaxel | 18 Years - | Hellenic Oncology Research Group | |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | NCT03836157 | Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial Cle... | Mirvetuximab So... Bevacizumab | 18 Years - | University of Oklahoma | |
| Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | NCT02833701 | Glioblastoma Glioma | Ascorbic Acid Bevacizumab Laboratory Biom... Quality-of-Life... | 19 Years - | University of Nebraska | |
| Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer | NCT00281528 | Breast Neoplasm... Neoplasm Metast... | ABI-007 (Abraxa... bevacizumab | 18 Years - | Celgene | |
| CRLX101 Plus Bevacizumab in Advanced RCC | NCT01625936 | Renal Cell Carc... | CRLX101 (Cerule... Bevacizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | NCT00667342 | Osteosarcoma Malignant Fibro... | Bevacizumab Cisplatin Doxorubicin Methotrexate Ifosfamide etoposide Surgery Radiotherapy | - 30 Years | St. Jude Children's Research Hospital | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02839707 | Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... | Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy | NCT02329639 | Metastatic Brea... | genetic interac... | 18 Years - | University of Pisa | |
| Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) | NCT01770301 | Ovarian Sex-cor... | Paclitaxel Bevacizumab | 18 Years - | ARCAGY/ GINECO GROUP | |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192 | Ovarian Carcino... Primary Periton... | Pemetrexed Bevacizumab | 18 Years - | Washington University School of Medicine | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | NCT00559845 | Breast Cancer | 5-fluorouracil Epidoxorubicin Cyclophosphamid... Paclitaxel Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | NCT05330429 | Metastatic Colo... | Magrolimab Bevacizumab Irinotecan Fluorouracil Leucovorin | 18 Years - | Gilead Sciences | |
| Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | NCT04683965 | Colorectal Neop... | Pemetrexed TAS-102 Bevacizumab | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | NCT05760599 | Hepatocellular ... | Candonilimab Bevacizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | NCT00384176 | Colorectal Canc... | Cediranib Bevacizumab 5-fluorouracil ... Leucovorin (in ... Oxaliplatin (in... | 18 Years - 130 Years | AstraZeneca | |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | NCT02715531 | Solid Tumor | 5-FU Atezolizumab Bevacizumab Gemcitabine Leucovorin Nab-Paclitaxel Oxaliplatin Capecitabine Cisplatin | 18 Years - | Hoffmann-La Roche | |
| ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00404404 | Breast Cancer | bevacizumab paclitaxel albu... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
